Abstract
Biomarkers are measurable indicators of a biological state or condition. In the context of COVID-19, biomarkers can be used to diagnose the disease, monitor its progression, and evaluate the effectiveness of treatments. One common biomarker for COVID-19 is the presence of viral RNA in a patient’s respiratory samples, as detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests. Antibody tests, which detect antibodies against the SARS-CoV-2 virus in a patient’s blood, can also be used as biomarkers, although they may not be as reliable in the early stages of infection. Other biomarkers that have been studied in the context of COVID-19 include proinflammatory cytokines, such as interleukin-6 (IL-6), which are known to be elevated in patients with severe disease. There are also several biomarkers being studied for their potential use as indicators of disease severity or risk of progression to severe disease. It’s important to note that biomarkers are changing rapidly as more research is being done on COVID-19, and new biomarkers are being discovered and characterized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
